FindTrial
Sign In

Establishment and validation of predictive ability model of biological agent treatment response in patients with inflammatory bowel disease

Establishment and validation of predictive ability model of biological agent treatment response in patients with inflammatory bowel disease

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100052542
Enrollment
Unknown
Registered
2021-10-30
Start date
2021-11-01
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel disease

Interventions

Gold Standard:Clinical outcomes
Index test:Predictive&#32
model&#32
of&#32
biological&#32
agent&#32
treatment&#32
response&#32
in&#32
patients&#32
with&#32
inflammatory&#32
bowel&#32
disease.

Sponsors

Qilu Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. In active or remission stage, meet the diagnostic criteria of ulcerative colitis and be confirmed by histopathology and endoscopy; 2. In active or remission stage, meet the diagnostic criteria of Crohns' disease, and be confirmed by histopathology and endoscopy; 3. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Serious infection; 2. Complicated with medical diseases such as liver and kidney insufficiency; 3. Pregnant women or lactating women; 4. Malignant tumor; 5. Changes of intestinal inflammation caused by other reasons, such as bacterial enteritis, amoebic enteritis, etc.

Design outcomes

Primary

MeasureTime frame
Expression level of candidate genes;Accuracy, specificity, sensitivity;—

Countries

China

Contacts

Public ContactYu Yanbo

Qilu Hospital of Shandong University

yuyanbo2000@126.com+86 13658610919

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026